Anagrelide

Active ingredient description

Anagrelide is an inhibitor of cyclic AMP phosphodiesterase III and suppress expression of transcription factors including GATA-1 and FOG-1 required for megakaryocytopoiesis, ultimately leading to reduced platelet production.

Medicine classification

This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:

ATC code
Group title
Classification
Anagrelide
L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01X Other antineoplastic agents → L01XX Other antineoplastic agents
Discover more medicines within L01XX35

Medicines

Anagrelide is the active ingredient of these drugs:

Drug
Countries

Brazil Canada Hong Kong New Zealand Singapore

Austria

Poland

Estonia Lithuania

Poland

Brazil

Austria Lithuania Poland

Austria Cyprus Estonia Finland France

Austria Germany

Product monographs

Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):

Title
Type
Country
Summary of Product Characteristics (SPC)
Structured Product Labeling (SPL/PLR)
US

Structural formula

Graphic representation of the active ingredient's molecular structure

Molecular mass: 256.088 g/mol

External identifiers

CAS Substance: 68475-42-3
DrugBank Drug: DB00261
KEGG Drug: D07455
RxNorm Ingredient: 596724
SNOMED-CT Concept: 372561005
Anagrelide (substance)
UNII Identifier: K9X45X0051
ANAGRELIDE